Company Name: Bionomics
Announcement Date: 22/09/2016
Announcement Category: Awards/recognition, Investment, Other, Product launch/update
Announcement Content:
BNO.AX: Whoomp There It Is! Looking Like a Paradigm Shift? Target to A$2.60
The Phase II BNC210 has delivered, meeting primary and secondary
endpoints in treating generalized anxiety disorder (GAD) in an acute setting.
There are two key takeaways from the study, in our belief, 1) brain systems
involved with anxiety are being engaged effectively (several parameters tested)
and 2) we believe these data significantly increase the partnering potential
for BNC210. Recall Merck (MRK-NC) has already signed two separate
partnerships with Bionomics. Reiterate Buy; target to A$2.60 from A$1.50.
Announcement URL: http://bit.ly/2cpR9Xw
About Bionomics:
Bionomics is an Adelaide-based biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible.
Go to Company Profile for: Bionomics
Announcement Contact: [email protected]
